Report cover image

Cancer Drugs Market

Publisher Coherent Market Insights
Published Jul 23, 2025
Length 150 Pages
SKU # CMI20302994

Description

Cancer is a most lethal disease in which some of the body's cells grow uncontrollably and spread to other parts of the body. Cancer drugs, such as chemotherapy, hormone therapies, targeted cancer drugs, immunotherapy drugs, and bisphosphonates, among others, are used to treat different types of cancer. Thus, with the rise in burden of cancer, the demand for safe and effective cancer drugs is also increasing with a rapid pace, worldwide.

Market Dynamics

Increasing prevalence of cancer, growing geriatric population, high demand for safe and effective cancer drugs, increasing awareness among people about a cancer and cancer drugs, and increasing number of cancer treatment centres are factors expected to augment the growth of the global cancer drugs market during the forecast period.

For instance, according to the American Cancer Society (ACS), in 2023, more than 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. While, in 2022, around 1.9 Billion new cancer cases and 609,360 cancer deaths were projected to occur in the U.S. Moreover, according to the cancer report by Indian Council of Medical Research (ICMR), India’s cancer cases could increase by 12% in the next five years, with around 1.5 Billion people projected to suffer from the non-communicable disease by 2025, up from 1.39 Billion in 2020.

Key features of the study
  • This report provides in-depth analysis of the global cancer drugs market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global cancer drugs market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Pfizer Inc., Novartis AG, Merck & Co., Inc., Celgene Corporation, AstraZeneca PLC, Astellas Pharma Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, and Johnson & Johnson (Janssen Global Services, LLC), among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer drugs market.
Market Segmentation
  • Global Cancer Drugs Market, By Drug Class Type
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy)
  • Global Cancer Drugs Market, By Indication
  • Lung Cancer
  • Stomach Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Liver Cancer
  • Esophagus Cancer
  • Cervical Cancer
  • Kidney Cancer
  • Bladder Cancer
  • Other Cancer
  • Global Cancer Drugs Market, By Geography
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa
  • GCC Countries
  • Israel
  • Rest of Middle East & Africa
  • Key Players Insights
  • Pfizer Inc.
  • Novartis AG
  • Merck & Co., Inc.
  • Celgene Corporation
  • AstraZeneca PLC
  • Astellas Pharma Inc.
  • AbbVie Inc.
  • Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson (Janssen Global Services, LLC)

Table of Contents

150 Pages
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snapshot, By Drug Class Type
Market Snapshot, By Indication
Market Snapshot, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Increasing burden of cancer across the globe
Adverse effects of cancer drugs
Growing demand for safe and effective drugs
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER’s Analysis
Merger and Acquisition Scenario
4. Global Cancer Drugs Market, By Drug Class Type, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 – 2032
Segment Trends
Chemotherapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Targeted Therapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Immunotherapy (Biologic Therapy)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Hormonal Therapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Cancer Drugs Market, By Indication, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 – 2032
Segment Trends
Lung Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Stomach Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Colorectal Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Breast Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Prostate Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Liver Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Esophagus Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Cervical Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Kidney Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Bladder Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Other Cancers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Cancer Drugs Market, By Region, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 – 2032
Segment Trends
North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2020-2032, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (USD Bn)
Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2020-2032, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (USD Bn)
Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2020-2032, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (USD Bn)
Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2020-2032, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (USD Bn)
Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2020-2032, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (USD Bn)
Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2020-2032, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (USD Bn)
7. Competitive Landscape
Pfizer Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Novartis AG
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Merck & Co., Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Celgene Corporation
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
AstraZeneca PLC
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Astellas Pharma Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
AbbVie Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
F. Hoffmann-La Roche Ltd.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Bristol-Myers Squibb Company
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Johnson & Johnson (Janssen Global Services, LLC)
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Analyst Views
8. Section
Research Methodology
About us

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us